SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934 (Amendment No. __)

Filed by the Registrant [X]

Filed by a Party other than the Registrant [    ]

     Check the appropriate box:

[   ]  Preliminary Proxy Statement
[   ]  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[   ]  Definitive Proxy Statement
[X]  Definitive Additional Materials
[   ]  Soliciting Material Pursuant to ss. 240.14a-12

Mylan Laboratories Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

[X]	No fee required.
[   ]	Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.

1)   Title of each class of securities to which transaction applies:

2)	Aggregate number of securities to which transaction applies:
3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4)	Proposed maximum aggregate value of transaction:
5)	Total fee paid:

[   ]	Fee paid previously with preliminary materials.
[   ]	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1)	Amount Previously Paid:
2)	Form, Schedule or Registration Statement No.:
3)	Filing Party:
4)	Date Filed:

For Immediate Release	CONTACTS:	Patrick Fitzgerald (Public Relations) Mylan Laboratories Inc. 724.514.1800
		Kris King (Investor Relations) Mylan Laboratories Inc. 724.514.1800

ISS Recommends Vote for Mylan Laboratories Board Nominees

PITTSBURGH, Oct. 18, 2005 — Mylan Laboratories Inc. (NYSE: MYL) today announced that Institutional Shareholder Services (ISS) has recommended that shareholders vote in favor of both proposals being presented by Mylan’s Board of Directors at the Annual Meeting of Shareholders on October 28, 2005. Specifically, ISS has recommended a vote for the election of each of Mylan’s nine Board nominees and for the ratification of the selection of Mylan’s independent registered public accounting firm.

In its report, ISS stated: “A substantial majority of the board members are independent outsiders and the key board committees include no insiders or affiliated outsiders.” Based on ISS’s standards of independence, six of Mylan’s nine director nominees, or two-thirds of the Board, were designated as independent outsiders. The key board committees referred to by ISS are the Audit Committee, the Compensation Committee and the Governance and Nominating Committee.

Milan Puskar, Mylan’s Chairman, commented: “We are very pleased with ISS’s voting recommendations and with the fact that under ISS’s exacting standards two-thirds of our directors were designated as independent outsiders. Mylan continues to be committed to strong corporate governance practices.”

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.